Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 21700909.
- Also identified by DOI 10.1164/rccm.201101-0138OC and PMC identifier 3262030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gastroesophageal reflux (GER) is highly prevalent in patients with idiopathic pulmonary fibrosis (IPF). Chronic microaspiration secondary to GER may play a role in the pathogenesis and natural history of IPF. To investigate the relationship between GER-related variables and survival time in patients with IPF. Regression analysis was used to investigate the relationship between GER-related variables and survival time in a retrospectively identified cohort of patients with well-characterized IPF from two academic medical centers. Two hundred four patients were identified for inclusion. GER-related variables were common in this cohort: reported symptoms of GER (34%), a history of GER disease (45%), reported use of GER medications (47%), and Nissen fundoplication (5%). These GER-related variables were significantly associated with longer survival time on unadjusted analysis. After adjustment, the use of GER medications was an independent predictor of longer survival time. In addition, the use of gastroesophageal reflux medications was associated with a lower radiologic fibrosis score. These findings were present regardless of center. The reported use of GER medications is associated with decreased radiologic fibrosis and is an independent predictor of longer survival time in patients with IPF. These findings further support the hypothesis that GER and chronic microaspiration may play important roles in the pathobiology of IPF.
Medical subject headings
- Fundoplication
- Gastroesophageal Reflux
- Histamine H2 Antagonists
- Idiopathic Pulmonary Fibrosis
- Proton Pump Inhibitors